000285741 001__ 285741
000285741 005__ 20260320151938.0
000285741 0247_ $$2doi$$a10.1016/j.expneurol.2026.115704
000285741 0247_ $$2pmid$$apmid:41765318
000285741 0247_ $$2ISSN$$a0014-4886
000285741 0247_ $$2ISSN$$a1090-2430
000285741 037__ $$aDZNE-2026-00298
000285741 041__ $$aEnglish
000285741 082__ $$a610
000285741 1001_ $$aKabaoglu, Burce$$b0
000285741 245__ $$aShift in motor-state equilibrium explains gait therapy effects of apomorphine in experimental Parkinsonism.
000285741 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2026
000285741 3367_ $$2DRIVER$$aarticle
000285741 3367_ $$2DataCite$$aOutput Types/Journal article
000285741 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1774016268_12445
000285741 3367_ $$2BibTeX$$aARTICLE
000285741 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285741 3367_ $$00$$2EndNote$$aJournal Article
000285741 520__ $$aGait impairments remain a major therapeutic challenge in Parkinson's disease (PD). Apomorphine is gaining renewed clinical attention with the expanding use of pump infusion systems. Yet the specific role of apomorphine on the neural regulation of gait has remained poorly characterized, limiting its targeted use for symptom-specific therapy in PD. Here, we examined the neurobehavioral effects of apomorphine on runway locomotion in the unilateral 6-hydroxydopamine (6-OHDA) rat model. Therapeutic drug doses significantly increased total walking distance, related to reduced akinesia and prolonged gait episodes. Conversely, 3D kinematic analysis revealed reduced limb velocities under medication. At the neural level, therapy doses selectively enhanced cortical high-gamma rhythms without substantially altering beta or low-gamma activity. Instead, beta and low-gamma oscillations were consistently suppressed during motor activity in both medication ON and OFF conditions. Neurobehavioral correlations showed that transitions into gait were facilitated by reductions in beta and low-gamma activity, whereas transitions to akinesia were primarily suppressed when high-gamma activity was elevated. Our findings highlight that cortical oscillations can serve as state specific biomarkers for gait impairments in PD. We further propose that the complex therapy effects of apomorphine are best explained by a shift in motor-state equilibrium that is defined by the transitions of akinesia, stationary movements and gait. Together, these insights establish a mechanistic framework to guide the development of targeted gait therapies in PD.
000285741 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285741 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285741 650_7 $$2Other$$aGait therapy
000285741 650_7 $$2Other$$aMotor control
000285741 650_7 $$2Other$$aNeural oscillations
000285741 650_7 $$2Other$$aParkinson's disease
000285741 7001_ $$aGarulli, Elisa L$$b1
000285741 7001_ $$aDe Sa, Rafael$$b2
000285741 7001_ $$aVogt, Arend$$b3
000285741 7001_ $$aBehrsing, Ruben$$b4
000285741 7001_ $$aSkrobot, Matej$$b5
000285741 7001_ $$aPaulat, Raik$$b6
000285741 7001_ $$aPollak, Patrick$$b7
000285741 7001_ $$aGuldin, Lynn S$$b8
000285741 7001_ $$aGerster, Moritz$$b9
000285741 7001_ $$aNeumann, Wolf-Julian$$b10
000285741 7001_ $$0P:(DE-2719)2811033$$aEndres, Matthias$$b11$$udzne
000285741 7001_ $$aHarms, Christoph$$b12
000285741 7001_ $$aWenger, Nikolaus$$b13
000285741 773__ $$0PERI:(DE-600)1466932-8$$a10.1016/j.expneurol.2026.115704$$gVol. 401, p. 115704 -$$p115704$$tExperimental neurology$$v401$$x0014-4886$$y2026
000285741 8564_ $$uhttps://pub.dzne.de/record/285741/files/DZNE-2026-00298.pdf$$yRestricted
000285741 8564_ $$uhttps://pub.dzne.de/record/285741/files/DZNE-2026-00298.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285741 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811033$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000285741 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285741 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-11-10$$wger
000285741 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEXP NEUROL : 2022$$d2025-11-10
000285741 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-10
000285741 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-10
000285741 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-10
000285741 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-10
000285741 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-10
000285741 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-10
000285741 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-10
000285741 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-10
000285741 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-10
000285741 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-10
000285741 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-10
000285741 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEXP NEUROL : 2022$$d2025-11-10
000285741 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lInterdisciplinary Dementia Research$$x0
000285741 980__ $$ajournal
000285741 980__ $$aEDITORS
000285741 980__ $$aVDBINPRINT
000285741 980__ $$aI:(DE-2719)1811005
000285741 980__ $$aUNRESTRICTED